June 2026 Research Update

Across this group of studies, earlier diagnosis is being approached from several angles: blood-based chemistry patterns, advanced brain scans that look at specific regions, and MRI-based mapping of nerve pathway damage. Overall, these studies suggest differences can be detected, but most results are exploratory and not yet ready to be used as stand-alone diagnostic tests.

In a small, prospective pilot study, a blood test approach (measuring many small molecules in serum) separated Parkinson disease from atypical parkinsonism and also showed separation between progressive supranuclear palsy and multiple system atrophy. The study detected 241 metabolites and the main differences clustered around carbohydrate use, redox balance (how the body handles oxidative stress), lipid handling, and phosphate-related pathways. [1]

In an exploratory imaging study focused on the parkinsonian subtype of multiple system atrophy, a dopamine-related PET scan pattern differed from Parkinson disease in where the signal was reduced. Multiple system atrophy showed lower uptake in the caudate and cerebellum, while Parkinson disease showed a different pattern and the putamen signal did not separate the two groups in this study. [2]

A diffusion MRI framework aimed to capture disease-specific patterns of axonal (nerve fiber) damage across several brain disorders and also produce a single-patient z-score style report. For multiple system atrophy, the group-level pattern emphasized pontocerebellar and corticospinal tracts, matching known areas often affected in the disease, but the authors noted the need for external validation and reliability testing. [3]

One cohort study evaluated a structured symptom scale for people with REM sleep behavior disorder who did not yet have a diagnosis of Parkinson disease, dementia with Lewy bodies, or multiple system atrophy. The Prodromal Synucleinopathy Rating Scale scores lined up moderately to strongly with established tests across thinking, mood/behavior, movement, autonomic symptoms, sleepiness, and smell, and it showed good rater-to-rater consistency. The scale is meant to measure early symptom burden for research, such as future prevention trials, and was not tested for telling these conditions apart. [4]

A large autopsy-confirmed brain bank analysis, spanning multiple movement disorders, found that clinical diagnoses before death did not always match the pathology seen at autopsy, with misdiagnosis rates around 10 to 20%. It also showed that mixed pathologies were common, which helps explain why early symptoms can overlap between conditions and why better early diagnostic tools are needed. [5]

A retrospective ataxia study highlighted another challenge relevant to earlier recognition: some people initially suspected to have autoimmune cerebellar ataxia were later reclassified as having neurodegenerative disease, and baseline imaging did not clearly identify who would be reclassified. This shows that early cerebellar symptoms can be hard to sort out, even with imaging, and diagnoses may change over time. [6]

For patients and caregivers, these studies mainly show where research is heading rather than changing what happens in clinic right now. Blood-based metabolite patterns, specialized PET scan readouts, and advanced MRI mapping are being explored as ways to distinguish multiple system atrophy from look-alike conditions earlier, while structured symptom scales aim to track early disease features in research settings. What remains uncertain is how well these tools work across many hospitals, scanners, and patient groups, and whether they can reliably identify multiple system atrophy early enough to improve care planning and research enrollment.

Two observational studies followed people with multiple system atrophy (MSA) over time and found a steady worsening in standard symptom and movement rating scores, supporting that MSA typically progresses over months rather than years. They also suggest that a simple test of sweat gland nerve function may help track how severe MSA is and how it changes over time, although this needs confirmation across more settings. [7] [8]

In a 12-month multicenter study of 89 Chinese adults with early possible or probable MSA, the Total UMSARS (a combined score of daily function and motor exam) increased by about 15 points per year on average. The rate of worsening was similar in the movement-predominant form (MSA-P) and the balance/coordination-predominant form (MSA-C) in this cohort. [7]

In a separate prospective single-center cohort of 175 people with possible or probable MSA in France, electrochemical skin conductance (ESC), a measure from a Sudoscan device that reflects sweat-nerve function, declined year by year. Lower ESC values went along with worse UMSARS scores, and ESC predicted UMSARS scores more accurately than changes in blood pressure when standing in this dataset. [8]

In the same French cohort, higher ESC over time was linked to longer survival, while higher UMSARS scores over time were linked to shorter survival. The study reported a median survival of 46.2 months in this clinic-based group, but this number may not apply to every person with MSA because survival can vary by who is included and how they are followed. [8]

For patients and caregivers, these studies add real-world numbers showing that MSA commonly worsens in measurable ways over a year, even early in the condition, and that the pace may look similar across major clinical subtypes in at least one cohort. They also introduce ESC (a sweat-nerve function test) as a potential way to monitor severity and changes over time, and possibly relate to survival, but it is not yet clear how well ESC performs across different countries, clinics, and stages of MSA. These results mainly help set expectations for research tracking and may inform how future studies measure progression, while leaving uncertainty about how accurately any single average reflects an individual persons course. [7] [8]

Across these studies, survival differences in multiple system atrophy (MSA) were most closely tied to how affected a person already was at the time they were measured, especially when autonomic (automatic body function) problems were more widespread. Overall, measures reflecting disability and autonomic burden tended to point in the same direction: more severe baseline impairment went along with shorter survival. [9] [8] [10]

In a small early-stage cohort (about 60 people), a data-driven group with extensive autonomic symptoms had a shorter median survival than a group with more restricted autonomic symptoms. However, when the analysis accounted for baseline functional impairment and how long symptoms had been present at enrollment, the survival difference was largely explained by those baseline severity factors rather than the subtype label itself. [9]

In a larger single-center study of 175 people, a sweat-gland nerve function measure (electrochemical skin conductance, measured with Sudoscan) declined over time and closely tracked worsening on standard MSA severity scales. People with higher electrochemical skin conductance over time tended to live longer, and this measure predicted clinical severity better than simple blood pressure drop measurements during standing in that study. [8]

A multicenter cohort of 391 people used standard clinical information to build a model that estimated individualized survival, with a random-forest survival approach using 11 predictors performing best in that dataset. This supports the idea that combining multiple features (rather than relying on a single symptom) can improve survival estimation, although the specific predictor list and how well it transfers to other settings are not detailed in the summary provided here. [10]

For patients and caregivers, these results mainly help explain why different people with MSA can have different survival timelines: studies repeatedly linked shorter survival to greater overall impairment and broader autonomic involvement at the time of assessment, and one clinic-based sweat test both tracked progression and related to survival. This is useful background for understanding research discussions about prognosis and monitoring, but it does not mean any single test can predict an individual person's course with certainty, and results may vary by center and patient group.

Across these papers, supportive care approaches aimed at daily function: improving balance and walking in rehabilitation, and reducing choking and aspiration in severe swallowing problems. The evidence is early, with one small before-after rehabilitation series and one single-patient surgical report, so it is not yet clear how well results generalize to most people with multiple system atrophy (MSA).

In an exploratory inpatient rehabilitation case series that included people with extrapyramidal disorders (including MSA), 5 of 7 participants completed 10 short sessions of immersive virtual reality training while supported by a body-weight support system. Balance scores improved after the program, and walking speed increased but did not reach statistical significance in this small sample. [11]

Safety and comfort were a focus in this rehabilitation study: there were no serious adverse events and no falls during training, with fatigue and brief symptoms like dizziness or eyestrain reported. Participants also rated satisfaction, enjoyment, and sense of immersion as high. [11]

A separate case report described one 70-year-old man with MSA and severe swallowing difficulty who had ongoing silent aspiration despite prior interventions. After a surgical procedure combining subglottic laryngeal closure with cricopharyngeal myotomy, aspiration was prevented, the upper esophageal sphincter opening improved, and partial eating by mouth was resumed. [12]

For patients and caregivers, these studies mainly add background about the range of supportive options that clinicians may consider: structured balance training tools in a supervised rehabilitation setting, and (in selected situations) more invasive swallowing-focused procedures to address aspiration risk. What remains uncertain is who is most likely to benefit, how long any gains last, and how these approaches compare with other rehabilitation methods or swallowing treatments, since the reports were small and did not include control groups. [11] [12]

Across the research in this group, the main message comes from lab-based animal work: diet-related metabolic stress may interact with multiple system atrophy (MSA) brain changes. Because this evidence comes from a mouse model rather than people, it suggests a possible link but does not show what happens in patients. [13]

In PLP-SYN transgenic mice (a commonly used MSA model), 4 months of a high-fat diet led to worse glucose regulation and more insulin resistance than in wild-type mice on the same diet. [13]

The same high-fat diet also appeared to worsen MSA-like brain and movement changes in the PLP-SYN mice, including more alpha-synuclein accumulation, more loss of dopamine-related nerve cells, and faster decline in fine motor function compared with PLP-SYN mice on a standard diet. [13]

For patients and caregivers, this study is best viewed as background research about how metabolism and diet could affect disease processes in MSA, not as evidence of a specific lifestyle effect in people. It raises the possibility that changes in blood sugar regulation and insulin resistance could influence MSA-related brain changes, but this remains uncertain without human studies. More research in patients would be needed to know whether similar relationships exist and whether they meaningfully affect symptoms or progression. [13]

Across these studies, the common thread is that alpha-synuclein (a brain protein involved in several movement disorders) can behave in a prion-like way in lab systems, meaning misfolded forms can encourage more alpha-synuclein to misfold. In a mouse model designed to mimic MSA biology, higher alpha-synuclein levels inside oligodendrocytes (support cells that make myelin) made it easier for seeded clumps to build up, pointing to a possible rate-limiting step in MSA-type cell damage. [14] [15]

In a transgenic mouse model with human alpha-synuclein overexpressed in oligodendroglia, injecting alpha-synuclein preformed fibrils led to more oligodendroglial insoluble aggregates over time than in wild-type mice, along with higher overall seeding activity in the brain. MSA-derived seeds produced more oligodendroglial inclusions than Parkinson's disease (PD)-derived seeds in these transgenic mice, supporting the idea that both the type of seed and the amount of alpha-synuclein inside the cell affect how much clumping occurs. [14]

A separate experimental workflow showed that alpha-synuclein secreted from cells, and alpha-synuclein enriched from saliva samples from people with PD, could retain modifications such as truncation and phosphorylation while still showing strong seeding activity in amplification tests. In cell models, the enriched material could also propagate misfolded species across cells, supporting the broader concept that alpha-synuclein can move between cells and carry seeding ability. [15]

This is mainly background research that helps explain how MSA may start and spread at a cell level, especially why oligodendrocytes develop the characteristic alpha-synuclein clumps. It does not yet show what happens in every person with MSA, because key results come from mouse and laboratory systems, and the saliva work in this set was done in Parkinson's disease rather than MSA. The uncertain parts include how these seeding processes unfold over time in living people with MSA, and which steps are most important to target for future tests or biomarkers.

These papers focus on creating and refining tools that researchers use to test cellular ideas about MSA. One is a new induced pluripotent stem cell (iPSC) line made from a person with parkinsonian-type MSA, which can be turned into different cell types for lab studies. Another uses an MSA-like mouse model to explore how changing brain immune-like cells may influence symptoms and brain dopamine-related markers, with results that differed by sex in the animals. [16] [17]

A new iPSC line (NIMHi28-A) was generated from blood cells from one clinically diagnosed MSA patient of Indian origin using Sendai virus reprogramming. The iPSCs showed robust self-renewal and expressed key pluripotency markers, meaning they kept stem-cell-like features needed for disease modeling experiments. [16]

In a reanalysis of data from MBP29-h alpha-syn mice, the CSF1R inhibitor PLX5622 was used to deplete central nervous system myeloid cells (immune-like brain cells), and depletion happened faster in males than females. Dystonia-like behavior decreased mainly in males on PLX5622 (3 out of 12 treated males developed dystonia-like behavior compared with 14 out of 15 control males), while all females showed dystonia-like behavior in both treatment and control groups; dopamine-related fiber measures in the striatum increased in treated males. [17]

These studies add laboratory building blocks rather than direct answers about day-to-day care. Patient-derived iPSCs can help researchers test how specific cell types behave in MSA and how alpha-synuclein-related changes might develop, but this is still early-stage and based on one person. The mouse results suggest immune-like brain cells could influence MSA-like movement features in a sex-dependent way in that model, but it remains uncertain how closely this matches MSA in humans and whether similar differences would be seen in people.

Across these papers, the common thread is that clinic structure and careful symptom evaluation can shape how supported patients feel and can help clinicians sort out complex problems. One study focused on patient experience in a specialty clinic, and one case report highlighted a specific diagnostic clue for dizziness when standard imaging did not explain symptoms. Together, they show both the value of coordinated services and the limits of relying on a single test like an MRI alone. [18] [19]

In a single-center satisfaction survey study of an interdisciplinary clinic for atypical parkinsonism (including multiple system atrophy, progressive supranuclear palsy, and corticobasal syndrome), respondents reported high satisfaction across multiple areas of care. The "Services" category was the strongest predictor of overall experience, suggesting that practical supports such as coordination, referrals, and access may matter as much as the clinician visit itself. Many respondents also said they would recommend the clinic and felt the recommendations would help with disease challenges, while open-ended comments raised issues like care partner concerns, uncertainty about the future, and billing. [18]

A separate case report described one 62-year-old man with heavy alcohol use and persistent, hard-to-characterize dizziness and falls, where brain MRI did not show an explanation. Specialized eye movement testing (videonystagmography) found periodic alternating nystagmus, which helped point clinicians toward MRI-negative Wernicke encephalopathy; symptoms and function fully reversed after vitamin replacement and alcohol cessation. Because this is one patient, it cannot show how often this happens, but it illustrates how focused testing can sometimes reveal treatable causes of symptoms that might otherwise be mistaken for a progressive neurologic condition. [19]

For people living with multiple system atrophy and their caregivers, this set of papers mainly informs how care can be organized and how complex symptoms may be evaluated in real clinics. The satisfaction survey suggests patients may especially value the service and coordination parts of specialty care, but it does not prove that such clinics change long-term health outcomes and it may not reflect the views of people who did not respond to the survey. The single-patient report is background context showing that dizziness and autonomic-type symptoms can sometimes have more than one contributing cause, and that additional tests beyond an MRI may occasionally clarify what is happening, but it does not establish a general approach for everyone. [18] [19]